In Q1 2023, Cormorant Asset Management held 49 positions worth $1.2B. They initiated 49 new positions. Their largest holding was RXDX ($177.6M).
Frequently asked questions
What stocks did Cormorant Asset Management own in Q1 2023?
Cormorant Asset Management held 49 biotech stocks in their 13F portfolio in Q1 2023. Their top positions include RXDX, MLTX, BMEA, APLS, BBIO. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Cormorant Asset Management's portfolio worth in Q1 2023?
Cormorant Asset Management's tracked biotech portfolio was worth $1.2B across 49 positions, with total assets under management of approximately $4B. Portfolio values are based on 13F filings with the SEC.
What did Cormorant Asset Management buy in Q1 2023?
Cormorant Asset Management initiated 49 new positions in Q1 2023, including RXDX, MLTX, BMEA, APLS, BBIO and 44 more. They also increased 0 existing positions.
What did Cormorant Asset Management sell in Q1 2023?
Cormorant Asset Management did not fully exit any positions in Q1 2023.
Is Cormorant Asset Management a biotech fund?
Healthcare-focused crossover fund that invests from late-stage private through public markets. Known for concentrated, high-conviction positions in clinical and commercial-stage biotech companies with strong scientific differentiation.
Want AI analysis, insider signals, and catalyst overlays for Cormorant Asset Management?
View latest Cormorant Asset Management portfolio →